Abstract
Introduction

34
"Because antibiotic resistance occurs as part of a natural evolution 35 process, it can be significantly slowed but not stopped. Therefore, new 36 antibiotics will always be needed to keep up with resistant bacteria." However, the magnitude of this fitness cost is hotly debated, especially in the context of 65 MRSA control (25, 26) , and, in any event, intensive medical interventions such as 66 patient isolation are not a practical or economical option in many circumstances.
67
In this paper, we ask: when it is possible to create net selection against resistance, even 68 when (i) there are no biological fitness costs associated with resistance, (ii) the best 69 available treatment cannot be withheld from any patient, and (iii) all non-antibiotic 70 intervention options are only moderately effective. We define "net selection against 71 resistance" as maintaining the fitness of one or more resistant strains below that of the 72 drug-sensitive strain, so that the frequency of these resistant strains will decline toward 73 zero. This can be accomplished, generally speaking, when diagnostics permit medical 74 personnel to artificially shape the pathogen fitness landscape so that resistant strains 75 are disproportionately disadvantaged. We show that the potential to reduce or even (ii) Pan resistance: are untreatable pan-resistant strains already in circulation? Table 1 80 offers a preview of our main findings in a simple setting with two equally-effective 81 antibiotic-treatment options, "drug 1" (first-line treatment to which resistance has already 82 emerged in the target-pathogen population) and "drug 2" (second-line treatment to 83 which resistance may or may not have already emerged). resistant" strain that remains sensitive to drug 2 (strain 1); a "drug-2-resistant" strain that 100 remains sensitive to drug 1 (strain 2); and a "pan-sensitive" strain that can be effectively 101 treated with either drug (strain 0) (Fig 1A) . include: point-of-care RD (POC-RD) with an obligate pathogen (Case #1, Fig 1B) ; POC-
125
RD with an opportunistic pathogen (Case #2, Fig 1C) 
131
Notation Details
Pathogen strains and pathogen-lifestyle parameters Drugs = 1,2 are available to treat infections caused by the target pathogen.
Each strain is named for the drugs (if any) X = 0, 1, 2, 12 to which it is resistant: strain 0 is susceptible to both drugs ("pan-sensitive"); strain 1 is resistant only to drug 1; strain 2 is resistant only to drug 2; and strain 12 is 8 resistant to both drugs ("pan-resistant"). Drug-2-resistant strain: Since strain-2 infections are susceptible to drug 1 and therefore impact on the drug 1 resistant strain (Fig 2, strain I1 ). In the limit of no diagnostic delay
O . This implies that resistance to drug 1 (given 194 available drug 2) can be selected against even in the absence of resistance costs
195
( $ * (0) < 0) so long as either drug 2 is more effective than drug 1 or drug 2 is less 196 effective than drug 1 but transmission control is sufficiently effective that
Control of a circulating pan-resistant strain I12 is more challenging, even with POC-RD.
198
Absent fitness costs ( $% = 0), net selection against pan resistance can be maintained 
228
An implication of our analysis is that, for pathogens like S. pneumoniae, E. coli, H. reducing their opportunities for transmission from carriage.
296
In SI.C, we extend our analysis of the SCIS model to examine the potential of carriage 297 RD-based interventions to generate selection against resistance. A key result is that, in 298 order to select against drug-1-resistance, the drug-1-resistant strain must be discovered 299 while in carriage at a rate $ that exceeds the rate $ 0 at which the sensitive strain is The antibiotic-resistance crisis is placing increasing pressure on healthcare globally and 345 is widely viewed as a one-way street toward a dangerous "post-antibiotic world" (1, 4).
346
In this paper, we ask whether resistance diagnostics (RD), when combined with public 347 health interventions such as heightened transmission control (HTC) for drug-resistant 348 bacterial strains, can substantially change the trajectory of resistance evolution.
349
In the early decades of the antibiotic era, doctors had no choice but to treat and control
350
infection unconditionally, creating a selective pressure favoring strains that were 351 resistant to whatever antibiotic was being widely prescribed. In that context, once 352 resistant strains emerge with zero biological fitness costs, all antibiotics become
353
"exhaustible resources" whose value to society is diminished by use (2, 3). In this paper,
354
we show that exhaustible resource antibiotics can in principle be transformed into
355
"renewable resources" whose value to society can be maintained over time even as (Fig 2) , However, our conclusions depend critically on the life-history of the 490 target pathogen, with the message that reversing resistance in opportunistic pathogens 491 subject to 'bystander' selection is not generally plausible with POC-RD information 492 alone (Fig. 4) 
